Filgrastim for the treatment of hematopoietic acute radiation syndrome.
The U.S. Food and Drug Administration (FDA) recently approved Neupogen(®) (filgrastim) for the treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. It is the first medical countermeasure currently approved by the FDA for this indication under the criteria of the FDA "animal rule". This article summarizes the consequences of high-dose radiation exposure, a description of the hematopoietic acute radiation syndrome (H-ARS), the use of hematopoietic growth factors in radiation accident victims and current available treatments for H-ARS with an emphasis on the use of Neupogen in this scenario.
University of Maryland, School of Medicine, Dept. of Radiation Oncology, Baltimore, Maryland, USA. afarese@som.umaryland.edu.
A M
AM
Farese
University of Maryland, School of Medicine, Dept. of Radiation Oncology, Baltimore, Maryland, USA.
T J
TJ
MacVittie
D054508:Acute Radiation Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000818:Animals; D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D000069585:Filgrastim / Q000009:adverse effects / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects* / Q000528:radiation effects; D006412:Hematopoietic Stem Cells / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D011833:Radiation Injuries, Experimental; D011859:Radiography; D023481:Terrorism; D016896:Treatment Outcome
D059451:Biosimilar Pharmaceuticals; D000069585:Filgrastim
Acute radiation syndrome; Filgrastim; PEG-G-CSF; t-metHuG-CSF